Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2012

Open Access 01-12-2012 | Research article

Association of pre-transplant statin use with delayed graft function in kidney transplant recipients

Authors: Janske Reiling, David W Johnson, Peter S Kruger, Peter Pillans, Daryl R Wall

Published in: BMC Nephrology | Issue 1/2012

Login to get access

Abstract

Background

Administration of HMG-CoA reductase inhibitors (statins), prior to ischemia or prior to reperfusion has been shown to decrease ischemia-reperfusion renal injury in animal studies. It is unknown whether this protective effect is applicable to renal transplantation in humans. The aim of this study was to determine the relationship between prior statin use in renal transplant recipients and the subsequent risk of delayed graft function.

Methods

All patients who underwent deceased or living donor renal transplantation at the Princess Alexandra Hospital between 1 July 2008 and 1 August 2010 were included in this retrospective, observational cohort study. Graft function was classified as immediate graft function (IGF), dialysis-requiring (D-DGF) and non-dialysis-requiring (ND-DGF) delayed graft function. The independent predictors of graft function were evaluated by multivariable logistic regression, adjusting for donor characteristics, recipient characteristics, HLA mismatch and ischaemic times.

Results

Overall, of the 266 renal transplant recipients, 21% exhibited D-DGF, 39% had ND-DGF and 40% had IGF. Statin use prior to renal transplantation was not significantly associated with the risk of D-DGF (adjusted odds ratio [OR] 1.05, 95% CI 0.96 – 1.15, P = 0.28). This finding was not altered when D-DGF and ND-DGF were pooled together (OR 0.98; 95% CI 0.89-1.06, p = 0.56).

Conclusions

The present study did not show a significant, independent association between prior statin use in kidney transplant recipients and the occurrence of delayed graft function.
Literature
1.
Chang SH, Russ GR, Chadban SJ, Campbell SB, McDonald SP: Trends in kidney transplantation in Australia and New Zealand, 1993–2004. Transplantation. 2007, 84 (5): 611-10.1097/01.tp.0000280553.23898.ef.CrossRefPubMed
2.
Yarlagadda SG, Coca SG, Formica RN, Poggio ED, Parikh CR: Association between delayed graft function and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009, 24 (3): 1039-1047.CrossRefPubMed
3.
Rodrigo E, Ruiz JC, Piñera C, Fernández Fresnedo G, Escallada R, Palomar R, Cotorruelo JG, Zubimendi JA, de Francisco AL M, Arias M: Creatinine Reduction Ratio on Post Transplant Day Two as Criterion in Defining Delayed Graft Function. Am J Transplant. 2004, 4 (7): 1163-1169. 10.1111/j.1600-6143.2004.00488.x.CrossRefPubMed
4.
Vilar E, Varagunam M, Yaqoob MM, Raftery M, Thuraisingham R: Creatinine Reduction Ratio: A Useful Marker to Identify Medium and High-Risk Renal Transplants. Transplantation. 2010, 89 (1): 97-10.1097/TP.0b013e3181be3dd1.CrossRefPubMed
5.
Perico N, Cattaneo D, Sayegh MH, Remuzzi G: Delayed graft function in kidney transplantation. Lancet. 2004, 364 (9447): 1814-1827. 10.1016/S0140-6736(04)17406-0.CrossRefPubMed
6.
Rosenthal JT, Danovitch GM, Wilkinson A, Ettenger RB: The high cost of delayed graft function in cadaveric renal transplantation. Transplantation. 1991, 51 (5): 1115-1118. 10.1097/00007890-199105000-00035.CrossRefPubMed
7.
Narayanan R, Cardella CJ, Cattran DC, Cole EH, Tinckam KJ, Schiff J, Kim SJ: Delayed graft function and the risk of death with graft function in living donor kidney transplant recipients. Am J Kidney Dis. 2010, 56 (5): 961-970. 10.1053/j.ajkd.2010.06.024.CrossRefPubMed
8.
Jochmans I, Moers C, Smits JM, Leuvenink HGD, Treckmann J, Paul A, Rahmel A, Squifflet JP, van Heurn E, Monbaliu D: Machine Perfusion Versus Cold Storage for the Preservation of Kidneys Donated After Cardiac Death: A Multicenter, Randomized, Controlled Trial. Ann Surg. 2010, 252 (5): 756-10.1097/SLA.0b013e3181ffc256.CrossRefPubMed
9.
Irish WD, McCollum DA, Tesi RJ, Owen AB, Brennan DC, Bailly JE, Schnitzler MA: Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol. 2003, 14 (11): 2967-10.1097/01.ASN.0000093254.31868.85.CrossRefPubMed
10.
Daly PJA, Power RE, Healy DA, Hickey DP, Fitzpatrick JM, Watson RWG: Delayed graft function: a dilemma in renal transplantation. BJU Int. 2005, 96 (4): 498-501. 10.1111/j.1464-410X.2005.05673.x.CrossRefPubMed
11.
Kaisar MO, Johnson DW: Validation of a nomogram for predicting the likelihood of delayed graft function in Australian adult deceased donor renal transplant recipients. Nephrology. 2006, 11 (1): 78-79. 10.1111/j.1440-1797.2006.00532.x.CrossRefPubMed
12.
Meier-Kriesche HU, Arndorfer JA, Kaplan B: The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation. 2002, 73 (1): 70-10.1097/00007890-200201150-00013.CrossRefPubMed
13.
Donnahoo KK, Shames BD, Harken AH, Meldrum DR: Review article: the role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol. 1999, 162 (1): 196-203. 10.1097/00005392-199907000-00068.CrossRefPubMed
14.
Rc D, Marc A, de Vries B, Buurman WA: Apoptosis and inflammation in renal reperfusion injury. Transplantation. 2002, 73 (11): 1693-10.1097/00007890-200206150-00001.CrossRef
15.
16.
Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U: Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol. 2002, 13 (9): 2288-10.1097/01.ASN.0000026609.45827.3D.CrossRefPubMed
17.
Todorovic Z, Nesic Z, Stojanovic R, Basta-Jovanovic G, Radojevic-Skodric S, Velickovic R, Chatterjee PK, Thiemermann C, Prostran M: Acute protective effects of simvastatin in the rat model of renal ischemia-reperfusion injury: It is never too late for the pretreatment. J Pharmacol Sci. 2008, 107 (4): 465-470. 10.1254/jphs.SC0070374.CrossRefPubMed
18.
Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H: Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol. 2000, 23 (1): 13-17.CrossRef
19.
Slijper N, Sukhotnik I, Chemodanov E, Bashenko Y, Shaoul R, Coran AG, Mogilner J: Effect of simvastatin on intestinal recovery following gut ischemia-reperfusion injury in a rat. Pediatr Surg Int. 2010, 26 (1): 105-110. 10.1007/s00383-009-2508-6.CrossRefPubMed
20.
Dibazar F, Hajipour B, Hosseinian M, Hemmati M, Ghandiha A: Simvastatin decreases hepatic ischaemia/reperfusion-induced liver and lung injury in rats. Folia Morphol. 2008, 67 (4): 231-
21.
Nesic Z, Todorovic Z, Stojanovic R, Basta-Jovanovic G, Radojevic-Skodric S, Velickovic R, Chatterjee PK, Thiemermann C, Prostran M: Single-dose intravenous simvastatin treatment attenuates renal injury in an experimental model of ischemia-reperfusion in the rat. J Pharmacol Sci. 2006, 102 (4): 413-417. 10.1254/jphs.SCE06002X.CrossRefPubMed
22.
Slotta JE, Laschke MW, Schilling MK, Menger MD, Jeppsson B, Thorlacius H: Simvastatin Attenuates Hepatic Sensitization to Lipopolysaccharide After Partial Hepatectomy. J Surg Res. 2010, 162 (2): 184-192. 10.1016/j.jss.2009.03.057.CrossRefPubMed
23.
Govani MV, Kwon O, Batiuk TD, Milgrom ML, Filo RS: Creatinine reduction ratio and 24-hour creatinine excretion on posttransplant day two: simple and objective tools to define graft function. J Am Soc Nephrol. 2002, 13 (6): 1645-10.1097/01.ASN.0000014253.40506.F6.CrossRefPubMed
24.
Yarlagadda SG, Coca SG, Garg AX, Doshi M, Poggio E, Marcus RJ, Parikh CR: Marked variation in the definition and diagnosis of delayed graft function: a systematic review. Nephrol Dial Transplant. 2008, 23 (9): 2995-10.1093/ndt/gfn158.CrossRefPubMedPubMedCentral
25.
Consultation W: World Health Organization Technical Report Series. Obesity: preventing and managing the global epidemic. 2000
26.
Johnson DW, Saunders HJ, Field MJ, Pollock CA: In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity. Am J Physiol Renal Physiol. 1999, 276 (3): F467-
27.
Esmon CT: Why do animal models (sometimes) fail to mimic human sepsis?. Crit Care Med. 2004, 32 (5): S219-CrossRefPubMed
28.
Marshall JC: Modeling MODS: what can be learned from animal models of the multiple-organ dysfunction syndrome?. Intensive Care Med. 2005, 31 (5): 605-608. 10.1007/s00134-005-2595-3.CrossRefPubMed
29.
Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G: Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med. 2006, 32 (1): 75-79. 10.1007/s00134-005-2859-y.CrossRefPubMed
30.
Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004, 110 (7): 880-10.1161/01.CIR.0000138932.17956.F1.CrossRefPubMed
31.
Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, Venkatesh B: Continuation of Statin Therapy in Patients with Presumed Infection: A Randomised Controlled Trial. Am J Respir Crit Care Med. 2011, 183: 774-781. 10.1164/rccm.201006-0955OC.CrossRefPubMed
32.
Moran JL, Bristow P, Solomon PJ, George C, Hart GK: Mortality and length-of-stay outcomes, 1993–2003, in the binational Australian and New Zealand intensive care adult patient database*. Crit Care Med. 2008, 36 (1): 46-10.1097/01.CCM.0000295313.08084.58.CrossRefPubMed
33.
34.
Nijboer W, Schuurs T, Van Der Hoeven J, Leuvenink H, Van der Heide J, Van Goor H, Ploeg R: Effects of brain death on stress and inflammatory response in the human donor kidney. Elsevier. 2005, 37 (1): 367-369.
35.
Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ: Effect of Statin Use Within the First 24 Hours of Admission for Acute Myocardial Infarction on Early Morbidity and Mortality+. Am J Cardiol. 2005, 96 (5): 611-616. 10.1016/j.amjcard.2005.04.029.CrossRefPubMed
36.
Endres M, Laufs U: Discontinuation of statin treatment in stroke patients. Stroke. 2006, 37 (10): 2640-10.1161/01.STR.0000240690.69406.28.CrossRefPubMed
37.
Schouten O, Hoeks SE, Welten GMJM, Davignon J, Kastelein JJP, Vidakovic R, Feringa HHH, Dunkelgrun M, van Domburg RT, Bax JJ: Effect of statin withdrawal on frequency of cardiac events after vascular surgery. Am J Cardiol. 2007, 100 (2): 316-320. 10.1016/j.amjcard.2007.02.093.CrossRefPubMed
38.
Top 10 Drugs. Aust Prescrib. 2010, 33 (6): 181-
39.
Chong PH, Seeger JD, Franklin C: Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med. 2001, 111 (5): 390-400. 10.1016/S0002-9343(01)00870-1.CrossRefPubMed
40.
Gottmann U, Brinkkoetter PT, Hoeger S, Gutermann K, Coutinho ZM, Ruf T, Hui S, Liu Z, Schnuelle P, van der Woude FJ: Atorvastatin donor pretreatment prevents ischemia/reperfusion injury in renal transplantation in rats: possible role for aldose-reductase inhibition. Transplantation. 2007, 84 (6): 755-10.1097/01.tp.0000281410.85659.48.CrossRefPubMed
41.
Navaneethan SD, Nigwekar SU, Perkovic V, Johnson DW, Craig JC, Strippoli G: HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2009, 3: CD004289-PubMed
Metadata
Title
Association of pre-transplant statin use with delayed graft function in kidney transplant recipients
Authors
Janske Reiling
David W Johnson
Peter S Kruger
Peter Pillans
Daryl R Wall
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2012
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-13-111

Other articles of this Issue 1/2012

BMC Nephrology 1/2012 Go to the issue

Research article

Postdialysis blood pressure rise predicts long-term outcomes in chronic hemodialysis patients: a four-year prospective observational cohort study

Research article

The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study

Research article

The impact of an “acute dialysis start” on the mortality attributed to the use of central venous catheters: a retrospective cohort study

Case report

Chronic kidney disease, severe arterial and arteriolar sclerosis and kidney neoplasia: on the spectrum of kidney involvement in MELAS syndrome

Research article

Differences between hospitals in attainment of parathyroid hormone treatment targets in chronic kidney disease do not reflect differences in quality of care

Research article

Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits